GLPG Stock Recent News

Galapagos NV (NASDAQ:GLPG ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Relations Paul Stoffels - Chair of the Board & Chief Executive Officer Thad Huston - Chief Financial Officer & Chief Operating Officer Valeria Cnossen - General Counsel Jeevan Shetty - Head of Clinical Development Oncology John Mellors - Head of Cell Therapy Discovery & Early Development Conference Call Participants Xian Deng - UBS Phil Nadeau - TD Cowen Brian Abrahams - RBC Capital Markets Faisal Khurshid - Leerink Partners Judah Frommer - Morgan Stanley Sean McCutcheon - Raymond James Jacob Mekhael - KBC Securities Sebastiaan Van der Schoot - Van Lanschot Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2024 Financial Results and Business Update Conference Call.

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco. A live webcast of the presentation will be accessible on the Investors page of the Company's website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. In addition, Galapagos management will host a sell-side analyst breakfast in San Francisco on Tuesday, January 14, 2025 at 8:00 am PT. Analysts interested in attending should reach out the Galapagos Investor Relations team at ir@glpg.com.

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.

SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for its recently FDA cleared ATALANTA-1 clinical study in patients with relapsed/refractory non-Hodgkin lymphoma in the U.S. Galapagos (Euronext & Nasdaq: GLPG) is a clinical stage biotechnology company with operations in Europe.

Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.

Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.